Fig. 6

a The distribution of RNA-binding-protein recognition sites across differentially spliced genes between primary and recurrent GBM. b The frequencies of occurrences of RNA-binding protein motifs in differentially spliced genes between primary and recurrent GBM. c Alternative exon inclusion in MAP4K4. d Inferred binding sites for SRSF proteins in MAP4K4. e PSI values for junctions supporting exon 19 inclusion and others, compared between primary and recurrent GBM RNA-seq, using the in-house data. f As in e, but using public data from TCGA and INCB. g The frequencies of expression of exon-19 supporting neojunction sequences in primary vs. recurrent GBM, compared between our in-house data, TCGA and INCB data. h The frequencies of occurrence of MAP4K4 exon junctions supporting exon-19 inclusion in stem-like and non-stem-like neoplastic GBM cells. i The results of an extracellular matrix invasion assay comparing SRSF5 OE in U87 cells to controls, with and without TMZ treatment at the IC50 for 48 h